Stocklytics Platform
Asset logo for symbol ARCT
Arcturus Therapeutics Holdings
ARCT62
$18.35arrow_drop_up3.03%$0.53
Asset logo for symbol ARCT
ARCT62

$18.35

arrow_drop_up3.03%

Income Statement (ARCT)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT-$2.68M-$26.39M-$11.11M-$20.11M-$52.08M
EBITDA-$1.78M-$25.49M-$10.29M-$19.31M-$51.38M
gross Profit$45.07M$38.01M$27.39M$42.57M-$43.10M
NET Income-$17.21M-$26.81M-$8.57M-$16.22M-$52.55M
total Revenue$45.97M$32.59M$28.21M$43.37M$9.56M

Balance Sheet (ARCT)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt-$284.44M-$256.47M-$316.78M-$264.90M-$291.26M
stockholders Equity$258.58M$263.97M$278.51M$280.06M$285.17M
total Assets$388.60M$418.84M$429.40M$457.65M$430.64M
total Debt$30.88M$31.92M$30.21M$47.01M$32.20M
total Liabilities$130.02M$154.87M$150.88M$177.58M$145.47M

Cash Flow (ARCT)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow$2.36M$2.18M-$17.98M$21.84M$94.00K
free Cash Flow-$30.17M-$5.79M-$1.38M-$33.38M$50.45M
investing Cash Flow-----$354.00K
operating Cash Flow-$29.84M-$5.55M-$544.67K-$32.40M$50.80M

Arcturus Therapeutics Holdings (ARCT) Financials

Arcturus Therapeutics Holdings Inc (ARCT) is a biopharmaceutical company that focuses on developing RNA medicines. The company's income statement reflects its financial performance over a given period. It includes various components such as revenues, expenses, and net income. Arcturus Therapeutics Holdings Inc (ARCT) reported a gross profit of $XX million, which represents the revenue remaining after deducting the cost of goods sold. The company's EBIT (Earnings Before Interest and Taxes) was $XX million, indicating its operating profitability before taking into account interest and tax expenses. ARCT's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) stood at $XX million, which provides a clearer picture of the company's operating performance by excluding non-cash expenses.
Arcturus Therapeutics Holdings Inc (ARCT) also reported its net income from stockholders, which represents the company's profit after deducting all expenses, including taxes and interest. The total revenue generated by Arcturus Therapeutics Holdings Inc (ARCT) during the reported period was $XX million, highlighting the overall financial performance of the company. Moving on to the balance sheet, it provides an overview of ARCT's financial position at a specific point in time. The balance sheet includes information about the company's assets, liabilities, and stockholders' equity. ARCT's total assets amounted to $XX million, with a significant portion of it invested in cash equivalents.
Arcturus Therapeutics Holdings Inc (ARCT) also has a certain level of net debt, which represents the company's total debt minus its cash and cash equivalents. This can be an important factor to consider when analyzing ARCT's financial stability. The company's stockholders' equity represents the ownership interest in the business, and it amounted to $XX million. It indicates the value of the company's assets that belong to the shareholders. In addition to equity, the balance sheet also includes total liabilities, which stood at $XX million, reflecting the company's obligations and debts.
Analyzing the cash flow, Arcturus Therapeutics Holdings Inc (ARCT) provides information on how cash is generated and used within the company. Operating cash flow measures the cash generated from the company's core operations, and ARCT reported a positive operating cash flow of $XX million. This indicates that the company's operations are generating net cash inflows. In contrast, investing cash flow represents the cash used for investments in assets or acquisitions. ARCT's investing cash flow was $XX million, indicating its expenditure on capital assets or business acquisitions.
Financing cash flow represents the cash flow from activities related to financing, such as issuing or repurchasing stock, paying dividends, or borrowing. Arcturus Therapeutics Holdings Inc (ARCT) reported a financing cash flow of $XX million, reflecting its financial activities. Free cash flow measures the cash available after deducting capital expenditures from operating cash flow. It provides insight into the company's ability to generate cash for further investments or to return to shareholders. ARCT's free cash flow was $XX million.
In conclusion, Arcturus Therapeutics Holdings Inc (ARCT) has shown positive financial performance, with significant revenues and profits. The company's balance sheet indicates a strong financial position, with substantial assets and equity. ARCT's cash flow analysis highlights its ability to generate cash from operations and its prudent management of financial activities. With a focus on developing RNA medicines, Arcturus Therapeutics Holdings Inc is poised for continued growth and success in the biopharmaceutical industry.
add Arcturus Therapeutics Holdings  to watchlist

Keep an eye on Arcturus Therapeutics Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level